🔗 Share this article

During a time as head of the World Health Organization, a past official famously stated that all of the “easy” antibiotics had long since been discovered. The point was that in tackling the urgent threat of antibiotic-resistant bacterial infections, we would face difficulties to find new treatments – or conserve the current arsenal – without developing novel approaches of operating. This assessment was accurate.

A Slow and Unprofitable Pipeline

Since the late 2010s, just sixteen antimicrobial agents have gained widespread regulatory approval – primarily close relatives of drugs currently available and thus not expected to overcome bacterial resistance for long. The creation of novel compounds is a lengthy and financially unattractive endeavor, given that curative medicines are less lucrative as those treating chronic conditions. The scientific outlook remains grim.

A Glimmer of Optimism and a New Model

However, the recent announcement of a pair of novel regulator-approved drugs for gonorrhoea is good news and, importantly, confirms a innovative method of incentivising development. A particular of the recently approved medications, Zoliflodacin, is the product of a unique type of collaboration between a global health organization and a drug firm. The non-profit provided funding and organised testing phases to offset expenses and navigate approval processes. This sort of support in advance helps direct the industry towards areas of most pressing global need.

This approach and a separate praised revenue guarantee scheme – initiated to ensure income to firms that invest in specific antimicrobials – constitute the strongest chance of sustaining a trickle of new drugs from the current framework.

The Unavoidable Problem of Resistance

But even accelerating the development of compounds in the pipeline isn't sufficient. Zoliflodacin is sometimes described as a novel type of antimicrobial, indicating it attacks a component of the infectious bacteria that no other drug does, theoretically compelling the bacterium to begin anew in evolving a defense to it. Scientists and doctors are relieved to have a new drug for gonorrhoea – which has resistant strains to every known antibiotic – but caution that eventual drug resistance to this compound is certain.

As has become the norm with recent antimicrobials, exists consequently an debate about whether it should be held in reserve, restricted to highly resistant cases only – limiting its use to settings where sophisticated diagnostics is accessible. This sort of prudent strategy should be the worldwide norm, but frequently cannot be implemented easily in many regions.

A Dwindling Stream of Innovation

More broadly, it is difficult to see where the flow of other novel antimicrobials we require could possibly originate. The aforementioned comment nodded to the fact that searching the living world for biological compounds – as with the first antibiotic – has had declining success. The application of AI has been proposed to speed up the discovery process, although a much-celebrated initial discovery identified in recent years has not yet progressed past preclinical studies. Synthetic drugs, which are mainly or fully lab-created, are constantly in research, but often run up against the fundamental rules of molecular science – the fact that we imagine a compound does not guarantee we can create it easily.

Running Fast to Stand Still

The prevailing scientific evaluation is that when it comes to antibiotics, we must move with great speed indeed just to remain in the same place. Careful, internationally coordinated use is the sole method to preserve our therapeutic edge. Sadly, the magnitude of forthcoming breakthroughs is going to seem miserly in contrast to the curative bonanza of the 20th century.